Annovis Bio Shows Alzheimer’s Reversal in Humans in Phase II Study

Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.

The study involved patients with mild to moderate Alzheimer’s disease. After 25 days, patients showed a 4.4-point improvement in cognition compared to baseline and a 3.3-point improvement compared to placebo, using the 70-point, 11 item Alzheimer’s Disease Assessment Scale (ADAS-11).

In contrast, data from Biogen regarding aducanumab claims to improve cognition by 1.4 points over 18 months. The U.S. Food and Drug Administration (FDA) determination regarding that therapy is anticipated within the next few weeks. Likewise, Cassava reported a 1.6-point improvement in ADAS-Cog11 over six months.

In Parkinson’s disease patients, there were statistically significant improvements in speed, coordination and motor function, and inflammation was markedly lowered. The trial specifically measured complement C3, YKL40, sTREM2 and GFAP. The improvements were statistically significant when patients were compared at day 0 and day 25, and when placebo-treated patients are compared to Posiphen-treated patients after 25 days.

Leave a Comment